Combined Maxacalcitol/Betamethasone Butyrate Propionate Ointment Possesses Long‐Term Sustained Effects of Inducing Regulatory T Cells and Downregulating the Th17 Response, Even After Discontinuation of Its Application in Imiquimod‐Induced Psoriasiform Dermatitis
The Journal of Dermatology · 2026
DOI: 10.1111/1346-8138.70031 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Teruo Shimizu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Calcitriol, Th17 Cells, Psoriasis. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maruho Co., Ltd., Maruho.
Abstract (Originalsprache)
We often experience sustained improvement, even after discontinuation of treatment in psoriasis lesions treated with topical vitamin D 3 (VD 3 ) or the combination of topical corticosteroids and VD 3 . However, the underlying mechanisms of these sustained effects remain unclear. We explored mechanisms for the sustained effects of maxacalcitol (MCT) and combined MCT/betamethasone butyrate propionate (BBP) ointments using a murine psoriasiform dermatitis model induced by imiquimod (IMQ). IMQ was applied once daily to the shaved backs of mice for 6 days to induce psoriasiform dermatitis. MCT, BBP, combined MCT/BBP ointment, or their vehicles were treated for 3 days prior to IMQ application. IMQ was reapplied after 1, 2, or 3 weeks from the first IMQ application to investigate the sustained effects of their ointments. In the first application of IMQ, the administration of MCT, BBP, or MCT/BBP ointment improved clinical and pathological manifestations and reduced Th17‐related cytokines. Treatment with MCT or MCT/BBP showed an increase in IL‐10 mRNA expression and a higher count of Foxp3 + cells within the skin, but not in those with BBP. The induction of IL‐10 by MCT and MCT/BBP persisted until reapplication of IMQ 2 weeks later, although their effects diminished 3 weeks later. The reduction in Th17‐related cytokines was maintained up to 3 weeks later in MCT/BBP, whereas it was not observed 2 weeks later in MCT. In conclusion, MCT and MCT/BBP showed long‐term effects by induction of regulatory T cells and IL‐10. Additionally, MCT/BBP downregulated Th17‐related cytokines, which could contribute to the sustained improvement after discontinuation observed in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
- Maruho Co., Ltd., Osaka, Japan.
ORCID-Profile: Masahiro Kamata, Yayoi Tada
Förderung
- Maruho Co., Ltd.
- Maruho
Zitieren
APA
Shimizu, T., Kamata, M., Uratsuji, H., Okada, Y., Watanabe, A., Hiura, A., Tomura, Y., & Tada, Y. (2026). Combined Maxacalcitol/Betamethasone Butyrate Propionate Ointment Possesses Long‐Term Sustained Effects of Inducing Regulatory T Cells and Downregulating the Th17 Response, Even After Discontinuation of Its Application in Imiquimod‐Induced Psoriasiform Dermatitis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70031
Vancouver
Shimizu T, Kamata M, Uratsuji H, Okada Y, Watanabe A, Hiura A, et al. Combined Maxacalcitol/Betamethasone Butyrate Propionate Ointment Possesses Long‐Term Sustained Effects of Inducing Regulatory T Cells and Downregulating the Th17 Response, Even After Discontinuation of Its Application in Imiquimod‐Induced Psoriasiform Dermatitis. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70031
BibTeX
@article{Shimizu2026,
author = {Shimizu, Teruo and Kamata, Masahiro and Uratsuji, Hideya and Okada, Yoshiki and Watanabe, Ayu and Hiura, Azusa and Tomura, Yayoi and Tada, Yayoi},
title = {Combined Maxacalcitol/Betamethasone Butyrate Propionate Ointment Possesses Long‐Term Sustained Effects of Inducing Regulatory T Cells and Downregulating the Th17 Response, Even After Discontinuation of Its Application in Imiquimod‐Induced Psoriasiform Dermatitis},
journal = {The Journal of Dermatology},
year = {2026},
doi = {10.1111/1346-8138.70031}
}
EUVIMED